Clinicopathological features and prognosis of 60 patients with villoglandular adenocarcinoma*
| Clinical features | Value |
| Median (IQR) age | 42 (27–68） |
| Tumor size (mean±SD) | 2.12±1.78 |
| <2 cm | 17 (28.3) |
| 2–3.9 cm | 25 (41.7) |
| ≥4 cm | 18 (30.0) |
| FIGO stage (2009) | |
| IA2 | 4 (6.7) |
| IB1 | 39 (65.0) |
| IB2 | 11 (18.3) |
| IIA1 | 5 (8.3) |
| IIA2 | 1 (1.7) |
| Primary therapy | |
| Surgery | 50 (83.3) |
| NACT | 7 (11.7) |
| NAIC | 3 (5.0) |
| Surgery | |
| Radical hysterectomy | 55 (91.7) |
| Simple hysterectomy | 5 (8.3) |
| Surgical approach | |
| Laparoscopy | 23 (38.3) |
| Laparotomy | 37 (61.7) |
| Adjuvant treatment | |
| Radiotherapy | 2 (3.3) |
| Chemotherapy | 14 (23.3) |
| Radiotherapy and chemotherapy | 10 (16.7) |
| None | 34 (56.7) |
| Differentiation | |
| G1 | 15/35 (42.9) |
| G2 | 19/35 (54.3) |
| G3 | 1/35 (2.9) |
| Unknown | 25 |
| Lymphovascular invasion | |
| Yes | 2 (3.3) |
| No | 58 (96.7) |
| Depth of cervical interstitial infiltration | |
| ≤1/2 | 38/53 (71.7) |
| >1/2 | 15/53 (28.3) |
| Unknown | 7 |
| Uterine infiltration | |
| Yes | 4 (6.7) |
| No | 56 (93.3) |
| Lymph node metastasis | |
| Yes | 3 (5.4) |
| No | 53 (94.6) |
| Unknown | 4 |
| Median (IQR) follow-up (month) | 50.2 (5.1–154.6) |
| Recurrence/death | 0 |
*Results are number (%) unless stated otherwise.
NACT, neoadjuvant intravenous chemotherapy; ; NAIC, neoadjuvant arterial interventional chemotherapy.